Glioma-specific antigens for immune tumor therapy

Expert Review of Vaccines

Volumn 5, Issue 6, 2006, Pages 793-802

  Skog, Johan ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Brain tumor; Glioma; Immunotherapy; Vaccine

Indexed keywords

CARBOPLATIN; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GLYCOPROTEIN GP 100; HLA A24 ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; PROTEIN TYROSINE KINASE; SQUAMOUS CELL CARCINOMA ANTIGEN RECOGNIZED BY T CELLS 1; SURVIVIN; TEMOZOLOMIDE; TENASCIN; TUMOR VACCINE; TYROSINASE RELATED PROTEIN 1; TYROSINASE RELATED PROTEIN 2; TYROSINE KINASE WITH IMMUNOGLOBULIN AND EPIDERMAL GROWTH FACTOR HOMOLOGY DOMAIN 2; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANTIGEN FUNCTION; ANTIGEN STRUCTURE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG TARGETING; GLIOMA; HUMAN; IMMUNOLOGICAL TOLERANCE; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STROMA CELL;

ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CANCER VACCINES; GLIOMA; HUMANS;

EID: 33845876327     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.5.6.793     Document Type: Review

References (97)

1. CBTRUS. Statistical report: primary brain tumors in the United States, 1997-2001. In: Central Brain Tumor Registry of the United States. CBTRUS, Chicago, IL, USA (2004).
2. Dropcho EJ, Soong SJ. The prognostic impact of prior low grade histology in patients with anaplastic gliomas: a case-control study. Neurology 47(3), 684-690 (1996).
3. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl J. Med. 352(10), 987-996 (2005).
4. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71(8), 2585-2597 (1993).
5. Henson JW. Treatment of glioblastoma multiforme: a new standard. Arch. Neurol. 63(3), 337-341 (2006).
6. Hanahan, D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000).
7. Kankuri E, Cholujova D, Comajova M, Vaheri A, Bizik J. Induction of hepatocyte growth factor/scatter factor by fibroblast clustering directly promotes tumor cell invasiveness. Cancer Res. 65(21), 9914-9922 (2005).
8. Kawada M, Inoue H, Masuda, T, Ikeda D. Insulin-like growth factor I secreted from prostate stromal cells mediates tumor-stromal cell interactions of prostate cancer. Cancer Res. 66(8), 4419-4425 (2006).
9. Zhang J, Sarkar S, Yong VW. The chemokine stromal cell derived factor-1 (CXCL12) promotes glioma invasiveness through MT2-matrix metalloproteinase. Carcinogenesis 26(12), 2069-2077 (2005).
10. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59(19), 5002-5011 (1999).
11. Jodele S, Blavier L, Yoon JM, Declerck YA. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev. 25(1), 35-43 (2006).
12. Caussinus, E, Gonzalez C. Induction of tumor growth by altered stem-cell asymmetric division in Drosophila melanogaster. Nat. Genet. 37(10), 1125-1129 (2005).
13. Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63(18), 5821-5828 (2003). •• Identifies a cancer stem cell in glioma tumors.
14. Bachoo RM, Maher EA, Ligon KL et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 1(3), 269-277 (2002).
15. Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, Holland EC. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res. 62(19), 5551-5558 (2002).
16. Sanai N, Tramontin AD, Quinones-Hinojosa A et al. Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature 427(6976), 740-744 (2004).
17. Aboody KS, Brown A, Rainov NG et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc. Natl Acad. Sci. USA 97(23), 12846-12851 (2000). • Demonstrates how neural stem cells home to glioma tumors.
18. Khakoo AY, Finkel T. Endothelial progenitor cells. Annu. Rev. Med. 56, 79-101 (2005).
19. Rafii, S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat. Med. 9(6), 702-712 (2003).
20. Udani VM, Santarelli JG, Yung YC et al. Hematopoietic stem cells give rise to perivascular endothelial-like cells during brain tumor angiogenesis. Stem Cells Dev. 14(5), 478-486 (2005). • Highlights the differentiation potential of hematopoietic stem cells into endothelial cells during brain tumor-induced angiogenesis.
21. Garcia-Barros M, Paris F, Cordon-Cardo C et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300(5622), 1155-1159 (2003).
22. Machein MR, Renninger S, de Lima-Hahn E, Plate KH. Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol. 13(4), 582-597 (2003).
23. Stoll BR, Migliorini C, Kadambi A, Munn LL, Jain RK. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. Blood 102(7), 2555-2561 (2003).
24. Li H, Gerald WL, Benezra R. Utilization of bone marrow-derived endothelial cell precursors in spontaneous prostate tumors varies with tumor grade. Cancer Res. 64(17), 6137-6143 (2004).
25. Lyden D, Hattori K, Dias S et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7(11), 1194-1201 (2001).
26. Peters BA, Diaz LA, Polyak K et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat. Med. 11(3), 261-262 (2005).
27. Rajantie I, Ilmonen M, Alminaite A, Ozerdem U, Alitalo, K, Salven P. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 104(7), 2084-2086 (2004).
28. Ruzinova MB, Schoer RA, Gerald W et al. Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 4(4), 277-289 (2003).
29. Barker CF, Billingham RE. Immunologically privileged sites. Adv. Immunol. 25, 1-54 (1977).
30. Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J. Neurosci. Res. 28(2), 254-260 (1991).
31. Brooks WH, Markesbery WR, Gupta GD, Roszman TL. Relationship of lymphocyte invasion and survival of brain tumor patients. Ann. Neurol. 4(3), 219-224 (1978).
32. Frei K, Malipiero U, Piani, D, Fontana A. Microglia and tumor rejection. Neuropathol. Appl. Neurobiol. 20(2), 206-208 (1994).
33. Mariani CL, Kouri JG, Streit WJ. Rejection of RG-2 gliomas is mediated by microglia and T lymphocytes. J. Neurooncol. 79(3), 243-253 (2006).
34. Flugel A, Labeur MS, Grasbon-Frodl EM, Kreutzberg GW, Graeber MB. Microglia only weakly present glioma antigen to cytotoxic T cells. Int. J. Dev. Neurosci. 17(5-6), 547-556 (1999).
35. Taniguchi Y, Ono K, Yoshida, S, Tanaka R. Antigen-presenting capability of glial cells under glioma-harboring conditions and the effect of glioma-derived factors on antigen presentation. J. Neuroimmunol. 111(1-2), 177-185 (2000).
36. Platten M, Kretz A, Naumann U et al. Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann. Neurol. 54(3), 388-92 (2003).
37. Badie, B, Schartner J. Role of microglia in glioma biology. Microsc. Res. Tech. 54(2), 106-113 (2001).
38. Graeber MB, Scheithauer BW, KreutzbergGW. Microglia in brain tumors. Glia 40(2), 252-259 (2002).
39. Gomez GG, Kruse CA. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther. Mol. Biol. 10(a), 133-146 (2006).
40. Brooks WH, Netsky MG, Normansell DE, Horwitz DA. Depressed cell-mediated immunity in patients with primary intracranial tumors. Characterization of a humoral immunosuppressive factor. J. Exp. Med. 136(6), 1631-1647 (1972).
41. Fecci PE, Mitchell DA, Whitesides JF et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 66(6), 3294-3302 (2006). •• Highlights the role of regulatory T cells in immune suppression of glioma tumors.
42. Blume-Jensen, P, Hunter T. Oncogenic kinase signalling. Nature 411(6835), 355-365 (2001).
43. Pinkas-Kramarski R, Soussan L, Waterman H et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 15(10), 2452-2467 (1996).
44. Kim HH, Vijapurkar U, Hellyer NJ, Bravo D, Koland JG. Signal transduction by epidermal growth factor and heregulin via the kinase-deficient ErbB3 protein. Biochem. J. 334(Pt 1), 189-195 (1998).
45. Hueman MT, Stojadinovic A, Storrer CE et al. Analysis of naive and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine. Cancer Immunol. Immunother. 56(2), 135-146 (2007).
46. Barbacci EG, Guarino BC, Stroh JG et al. The structural basis for the specificity of epidermal growth factor and heregulin binding. J. Biol. Chem. 270(16), 9585-9589 (1995).
47. Stove, C, Bracke M. Roles for neuregulins in human cancer. Clin. Exp. Metastasis 21(8), 665-684 (2004).
48. Bigner SH, Humphrey PA, Wong AJ et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res. 50(24), 8017-8022 (1990).
49. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr. Relat. Cancer 8(2), 83-96 (2001).
50. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J. Clin. Oncol. 19(Suppl. 18), 32S-40S (2001).
51. Fernandes H, Cohen, S, Bishayee S. Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/δEGFR) expressed in cancer cells. J. Biol. Chem. 276(7), 5375-5383 (2001).
52. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD. The class III variant of the epidermal growth factor receptor (EGFRvIII), characterization and utilization as an immunotherapeutic target. J. Neurovirol. 4(2), 148-158 (1998).
53. Heimberger AB, Archer GE, Crotty LE et al. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 50(1), 158-164 (2002).
54. Heimberger AB, Crotty LE, Archer GE et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin. Cancer Res. 9(11), 4247-4254 (2003).
55. Peters KG, Kontos CD, Lin PC et al. Functional significance of Tie2 signaling in the adult vasculature. Recent Prog. Horm. Res. 59, 51-71 (2004).
56. Stratmann A, Risau, W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am. J. Pathol. 153(5), 1459-1466 (1998).
57. Carmeliet, P, Jain RK. Angiogenesis in cancer and other diseases. Nature 407(6801), 249-257 (2000).
58. Lee A, Frischer J, Serur A et al. Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling. Cancer Res. 66(8), 4378-4384 (2006).
59. De Palma M, Venneri MA, Galli R et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 8(3), 211-226 (2005).
60. Luo Y, Wen YJ, Ding ZY et al. Immunotherapy of tumors with protein vaccine based on chicken homologous Tie-2. Clin. Cancer Res. 12(6), 1813-1819 (2006).
61. Ventimiglia JB, Wikstrand CJ, Ostrowski LE, Bourdon MA, Lightner VA, Bigner DD. Tenascin expression in human glioma cell lines and normal tissues. J. Neuroimmunol. 36(1), 41-55 (1992).
62. Pas J, Wyszko E, Rolle K et al. Analysis of structure and function of tenascin-C. Int. J. Biochem. Cell Biol. 38(9), 1594-602 (2006).
63. Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein, P, Weis S. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 98(11), 2430-2439 (2003).
64. Carnemolla B, Castellani P, Ponassi M et al. Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am. J. Pathol. 154(5), 1345-1352 (1999).
65. Zalutsky MR. Current status of therapy of solid tumors: brain tumor therapy. J. Nucl. Med. 46(Suppl 1), 151S-156S (2005).
66. Imaizumi T, Kuramoto T, Matsunaga K et al. Expression of the tumor-rejection antigen SART1 in brain tumors. Int. J. Cancer 83(6), 760-764 (1999).
67. Shichijo S, Nakao M, Imai Y et al. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J. Exp. Med. 187(3), 277-288 (1998).
68. Yoshida, S, Tanaka R. Generation of a human leukocyte antigen-A24-restricted antitumor cell with the use of SART-1 peptide and dendritic cells in patients with malignant brain tumors. J. Lab. Clin. Med. 144(4), 201-207 (2004).
69. Imanishi T AT, Kimura A, Tokunaga K, Gojobori T. HLA 1991. Oxford University Press, Oxford, UK (1992).
70. Ambrosini G, Adida, C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3(8), 917-921 (1997).
71. Fukuda, S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol. Cancer Ther. 5(5), 1087-1098 (2006).
72. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo, T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 58(22), 5071-5074 (1998).
73. Monzo M, Rosell R, Felip E et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol. 17(7), 2100-2104 (1999).
74. Kato J, Kuwabara Y, Mitani M et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int. J. Cancer 95(2), 92-95 (2001).
75. Xie D, Zeng YX, Wang HJ et al. Expression of cytoplasmic and nuclear survivin in primary and secondary human glioblastoma. Br. J. Cancer 94(1), 108-114 (2006).
76. Jiao BH, Yao ZG, Geng SM, Zuo SH. Expression of survivin, a novel apoptosis inhibitor and cell cycle regulatory protein, in human gliomas. Chin. Med. J. (Engl.) 117(4), 612-614 (2004).
77. Chakravarti A, Noll E, Black PM et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J. Clin. Oncol. 20(4), 1063-1068 (2002).
78. Mahotka C, Liebmann J, Wenzel M et al. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ. 9(12), 1334-1342 (2002).
79. O'Connor DS, Wall NR, Porter AC, Altieri DC. A p34(cdc2) survival checkpoint in cancer. Cancer Cell 2(1), 43-54 (2002).
80. Uren AG, Wong L, Pakusch M et al. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr. Biol. 10(21), 1319-1328 (2000).
81. Sah NK, Khan Z, Khan GJ, Bisen PS. Structural, functional and therapeutic biology of survivin. Cancer Lett. (2006).
82. Tsuruma T, Hata F, Torigoe T et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J. Transl. Med. 2(1), 19 (2004).
83. Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH. HLA-B35-restricted immune responses against survivin in cancer patients. Int. J. Cancer 108(6), 937-941 (2004).
84. Fuessel S, Meye A, Schmitz M et al. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate 66(8), 811-821 (2006).
85. Rimoldi D, Romero, P, Carrel S. The human melanoma antigen-encoding gene, MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas. Int. J. Cancer 54(3), 527-528 (1993).
86. Chi DD, Merchant RE, Rand R et al. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am. J. Pathol. 150(6), 2143-2152 (1997).
87. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038), 1643-1647 (1991).
88. van Baren N, Bonnet MC, Dreno B et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol. 23(35), 9008-9021 (2005).
89. Liu G, Akasaki Y, Khong HT et al. Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene 24(33), 5226-5234 (2005).
90. Spaner DE, Astsaturov I, Vogel T et al. Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100. Cancer 106(4), 890-899 (2006).
91. Reyzer ML, Caprioli RM. MALDI mass spectrometry for direct tissue analysis: a new tool for biomarker discovery. J. Proteome Res. 4(4), 1138-1142 (2005).
92. Wibom C, Pettersson F, Sjostrom M, Henriksson R, Johansson, M, Bergenheim AT. Protein expression in experimental malignant glioma varies over time and is altered by radiotherapy treatment. Br. J. Cancer 94(12), 1853-1863 (2006), erratum in Br. J. Cancer 95(6), 766 (2006).
93. Phillips HS, Kharbanda S, Chen R et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9(3), 157-173 (2006).
94. Bodey B, Bodey B Jr, Siegel SE, Kaiser HE. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy. Anticancer Res. 20(4), 2665-2676 (2000).
95. + T cells. Immunology 107(1), 5-9 (2002).
96. Rea D, Havenga MJ, van Den Assem M et al. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J. Immunol. 166(8), 5236-5244 (2001).
97. Skog J, Edlund K, Widegren B, Salford LG, Wadell G, Mei YF. Efficient internalization into low-passage glioma cell lines using adenoviruses other than type 5: an approach for improvement of gene delivery to brain tumours. J. Gen. Virol. 85(Pt 9), 2627-2638 (2004).